CN101836725A - 红曲渣产品在制备降血脂保健食品方面的应用 - Google Patents
红曲渣产品在制备降血脂保健食品方面的应用 Download PDFInfo
- Publication number
- CN101836725A CN101836725A CN201010003099A CN201010003099A CN101836725A CN 101836725 A CN101836725 A CN 101836725A CN 201010003099 A CN201010003099 A CN 201010003099A CN 201010003099 A CN201010003099 A CN 201010003099A CN 101836725 A CN101836725 A CN 101836725A
- Authority
- CN
- China
- Prior art keywords
- food
- product
- red rice
- monascus
- haematochrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 55
- 235000007164 Oryza sativa Nutrition 0.000 title claims abstract description 37
- 210000004369 blood Anatomy 0.000 title claims abstract description 36
- 239000008280 blood Substances 0.000 title claims abstract description 36
- 240000007594 Oryza sativa Species 0.000 title claims abstract description 34
- 235000007189 Oryza longistaminata Nutrition 0.000 title claims abstract description 27
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims abstract description 33
- 239000007788 liquid Substances 0.000 claims abstract description 26
- 235000015895 biscuits Nutrition 0.000 claims abstract description 15
- 238000000855 fermentation Methods 0.000 claims abstract description 14
- 230000004151 fermentation Effects 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000005516 engineering process Methods 0.000 claims abstract description 6
- 235000013373 food additive Nutrition 0.000 claims abstract description 6
- 239000002778 food additive Substances 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 48
- 239000000047 product Substances 0.000 claims description 45
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 238000004040 coloring Methods 0.000 claims description 35
- 239000002893 slag Substances 0.000 claims description 33
- 239000000284 extract Substances 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 11
- 150000002632 lipids Chemical class 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 235000009566 rice Nutrition 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 230000036961 partial effect Effects 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 6
- 238000003809 water extraction Methods 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 241000209094 Oryza Species 0.000 claims 3
- 238000010298 pulverizing process Methods 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 48
- 235000012000 cholesterol Nutrition 0.000 abstract description 17
- 210000002966 serum Anatomy 0.000 abstract description 14
- 241001465754 Metazoa Species 0.000 abstract description 13
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 8
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract description 7
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 3
- 238000010171 animal model Methods 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- 239000003925 fat Substances 0.000 abstract 5
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 abstract 2
- 239000004459 forage Substances 0.000 abstract 2
- 150000001841 cholesterols Chemical class 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000007689 inspection Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 17
- 230000036541 health Effects 0.000 description 17
- 208000031226 Hyperlipidaemia Diseases 0.000 description 14
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 12
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- 230000037396 body weight Effects 0.000 description 10
- 229960004844 lovastatin Drugs 0.000 description 10
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 239000002699 waste material Substances 0.000 description 9
- 108010023302 HDL Cholesterol Proteins 0.000 description 8
- 108010028554 LDL Cholesterol Proteins 0.000 description 8
- 102000004895 Lipoproteins Human genes 0.000 description 8
- 108090001030 Lipoproteins Proteins 0.000 description 8
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 229960002662 propylthiouracil Drugs 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 230000003143 atherosclerotic effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 241000031003 Monascus ruber Species 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108700022737 rat Fat1 Proteins 0.000 description 3
- 229940026314 red yeast rice Drugs 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- 241001465318 Aspergillus terreus Species 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940099352 cholate Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- -1 hydroxymethyl glutaryl Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229930185723 monacolin Natural products 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000288049 Perdix perdix Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003208 anti-thyroid effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010100030992A CN101836725B (zh) | 2010-01-01 | 2010-01-01 | 红曲渣产品在制备降血脂保健食品方面的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010100030992A CN101836725B (zh) | 2010-01-01 | 2010-01-01 | 红曲渣产品在制备降血脂保健食品方面的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101836725A true CN101836725A (zh) | 2010-09-22 |
CN101836725B CN101836725B (zh) | 2013-03-06 |
Family
ID=42740605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010100030992A Expired - Fee Related CN101836725B (zh) | 2010-01-01 | 2010-01-01 | 红曲渣产品在制备降血脂保健食品方面的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101836725B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102273637A (zh) * | 2011-08-30 | 2011-12-14 | 广东医学院 | 红曲菌丝体提取物在制备预防骨质疏松保健食品及药品的应用 |
CN102334681A (zh) * | 2011-08-19 | 2012-02-01 | 广东轻工职业技术学院 | 一种红曲霉菌体滤渣制备可溶性降脂营养粉的方法 |
CN103613494A (zh) * | 2013-11-05 | 2014-03-05 | 广东医学院 | 以红曲菌丝体为原料提取辅酶q10的工艺及生产方法 |
CN103704690A (zh) * | 2013-12-12 | 2014-04-09 | 东莞市双红生物转化技术有限公司 | 红曲菌丝体复方降血脂功能食品及其制备方法 |
CN107865021A (zh) * | 2017-11-21 | 2018-04-03 | 北京工商大学 | 一种利用红曲菌丝体制备的红曲饼干及其方法 |
CN111513155A (zh) * | 2020-05-21 | 2020-08-11 | 云南中医药大学 | 一种防治脂代谢异常的组合物 |
CN112741246A (zh) * | 2019-10-30 | 2021-05-04 | 中粮营养健康研究院有限公司 | 具有调节血脂作用的组合物及其应用和功能性食品 |
CN113100337A (zh) * | 2021-05-14 | 2021-07-13 | 天津泽优饲料销售有限公司 | 红曲渣产品在制备饲料方面的应用 |
CN116870101A (zh) * | 2023-06-25 | 2023-10-13 | 汕头大学 | 一种红曲菌发酵产物在调节脂质代谢上的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1064524C (zh) * | 1996-01-09 | 2001-04-18 | 武汉多人多生物工程有限责任公司 | 真菌复合物及其制配方法 |
CN1081235C (zh) * | 1998-12-04 | 2002-03-20 | 陈远德 | 具有保健作用的食用糖 |
CN1778197A (zh) * | 2004-11-24 | 2006-05-31 | 徐维信 | 可降压降脂降糖黏性生物血宝的制作方法 |
-
2010
- 2010-01-01 CN CN2010100030992A patent/CN101836725B/zh not_active Expired - Fee Related
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102334681A (zh) * | 2011-08-19 | 2012-02-01 | 广东轻工职业技术学院 | 一种红曲霉菌体滤渣制备可溶性降脂营养粉的方法 |
CN102334681B (zh) * | 2011-08-19 | 2013-03-20 | 广东轻工职业技术学院 | 一种红曲霉菌体滤渣制备可溶性降脂营养粉的方法 |
CN102273637A (zh) * | 2011-08-30 | 2011-12-14 | 广东医学院 | 红曲菌丝体提取物在制备预防骨质疏松保健食品及药品的应用 |
CN102273637B (zh) * | 2011-08-30 | 2012-12-05 | 广东医学院 | 红曲菌丝体提取物在制备预防骨质疏松保健食品及药品的应用 |
CN103613494B (zh) * | 2013-11-05 | 2016-02-03 | 广东医学院 | 以红曲菌丝体为原料提取辅酶q10的工艺及生产方法 |
CN103613494A (zh) * | 2013-11-05 | 2014-03-05 | 广东医学院 | 以红曲菌丝体为原料提取辅酶q10的工艺及生产方法 |
CN103704690A (zh) * | 2013-12-12 | 2014-04-09 | 东莞市双红生物转化技术有限公司 | 红曲菌丝体复方降血脂功能食品及其制备方法 |
CN107865021A (zh) * | 2017-11-21 | 2018-04-03 | 北京工商大学 | 一种利用红曲菌丝体制备的红曲饼干及其方法 |
CN112741246A (zh) * | 2019-10-30 | 2021-05-04 | 中粮营养健康研究院有限公司 | 具有调节血脂作用的组合物及其应用和功能性食品 |
CN111513155A (zh) * | 2020-05-21 | 2020-08-11 | 云南中医药大学 | 一种防治脂代谢异常的组合物 |
CN111513155B (zh) * | 2020-05-21 | 2022-11-08 | 云南中医药大学 | 一种防治脂代谢异常的组合物 |
CN113100337A (zh) * | 2021-05-14 | 2021-07-13 | 天津泽优饲料销售有限公司 | 红曲渣产品在制备饲料方面的应用 |
CN116870101A (zh) * | 2023-06-25 | 2023-10-13 | 汕头大学 | 一种红曲菌发酵产物在调节脂质代谢上的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101836725B (zh) | 2013-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101836725B (zh) | 红曲渣产品在制备降血脂保健食品方面的应用 | |
CN105192832A (zh) | 一种益生菌发酵辣木叶的组合物及其制备方法和应用 | |
CN1259935C (zh) | 一种治疗高脂血症的药物 | |
CN106729092A (zh) | 一种含低聚木糖的降血脂制剂及其制备方法和应用 | |
CN104288345A (zh) | 一种辅助降血脂的中药组合物及其制备方法 | |
WO2015190872A1 (ko) | 스피루리나 추출물을 유효성분으로 함유하는 비만 예방 및 치료용 약학적 조성물 | |
CN101664180B (zh) | 一种具有保健功效的营养复合剂及其制备方法 | |
CN104388236A (zh) | 一种葡萄酒及其制备方法与应用 | |
CN112219956A (zh) | 降血脂降血糖的刺梨食用菌复合发酵饮料的制备及应用 | |
CN107375466A (zh) | 一种具有降血脂功能的药食两用发酵液及其制备方法 | |
CN103690821B (zh) | 一种辅助降血脂组合物 | |
CN104055947A (zh) | 一种含有葡萄提取物的中药组合物及制备方法 | |
Kuate et al. | The use of Cissus quadrangularis (CQR-300) in the management of components of metabolic syndrome in overweight and obese participants | |
CN102940650A (zh) | 用于解酒的蜂胶乙醇提取物、制备方法及在生产肠溶片中的应用 | |
CN110074392A (zh) | 一种解酒保肝养胃护肠组合物及其制备方法 | |
WO2019100843A1 (zh) | 一种浒苔多糖复合降血脂保健品及其制备方法 | |
CN101804083B (zh) | 松花粉及其提取物在治疗炎症性肠病中的用途及该提取物的制备方法 | |
CN106754057A (zh) | 一种保健红曲糯米酒及其制备方法 | |
CN107668722A (zh) | 大枣多糖、及其制备方法和含大枣多糖的食品 | |
CN106177227A (zh) | 一种增强人体免疫力的含辅酶q10的组合物 | |
CN112089784A (zh) | 中药组合物在制备预防、治疗动脉粥样硬化所致疾病的药物中的应用 | |
CN1660207A (zh) | 降低血脂和胆固醇的保健制剂及其生产方法 | |
CN105707568A (zh) | 一种具有辅助降血脂功能的α-亚麻酸软胶囊及制备方法 | |
CN109157548A (zh) | 一种具有抗疲劳和壮阳功能的组合物及制备方法 | |
CN104273527B (zh) | 一种保健组合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160204 Address after: 2-3, building 4, 1, Taoyuan Road, hi tech Industrial Development Zone, Songshan Lake, Guangdong, Dongguan, 523000 Patentee after: GUANGDONG SHENGYUAN ZHONGTIAN BIOTECHNOLOGY Co.,Ltd. Address before: 523808, 1, Xincheng Avenue, Songshan science and Technology Industrial Park, Guangdong, Dongguan Patentee before: Guangdong Medical College |
|
DD01 | Delivery of document by public notice |
Addressee: Wu Tie Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice |
Addressee: GUANGDONG SHENGYUAN ZHONGTIAN BIOTECHNOLOGY Co.,Ltd. Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: GUANGDONG SHENGYUAN ZHONGTIAN BIOTECHNOLOGY Co.,Ltd. Person in charge of patents Document name: Notice of Termination of Patent Rights |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130306 |